The Effect of the New Oral Hypoglycemic Agent A-4166 on Glucose Turnover in the High Fat Diet-Induced and/or in the Hereditary Insulin Resistance of Rats
- 1 January 1998
- journal article
- Published by Taylor & Francis in Archives of Physiology and Biochemistry
- Vol. 106 (4) , 325-332
Abstract
A-4166, a phenylalanine derivative, is a hypoglycemic agent, which has been shown to improve blood glucose levels mainly due to the rapid and short term stimulation of insulin release. Nevertheless, a possible extrapancreatic action of A-4166 has not yet been investigated. Therefore, insulin action (euglycemic hyperinsulinemic 6.4 mU.kg-1.min-1 clamp plus 3H-2-deoxyglucose tracer administration) was studied after 3 weeks on either standard (BD) or high fat (HF) diet in normal control (C) or in hereditary insulin resistant (hHTg) rats which were given a single dose of A-4166 (10 mg per kg BW, i.v.) 60 min after clamp commencement. HF feeding reduced the glucose infusion rate (GIR) required to maintain euglycemia to about 50% of C (p < 0.001). In hHTg rats, HF did not further pronounce the pre-existing decrease of GIR of hHTg animals fed BD. A-4166 changed GIR neither in C, nor in the hHTg group. The estimated glucose disposal (Rd) (C-BD: 32.3 +/- 1.9 vs C-HF: 25.5 +/- 1.9 mg.kg-1.min-1, p < 0.001) and glucose metabolic index (Rg') in skeletal muscles (Q. femoris: C-BD: 25.6 +/- 1.5 vs C-HF: 12.3 +/- 1.1 mmol.100 g-1.min-1, p < 0.001) were reduced by HF in control rats but were not restored by a concomitant bolus of A-4166. Nevertheless, in hHTg rats fed the HF diet a single dose of A-4166 brought back their Rd (hHTg-HF: 23.5 +/- 1.3 vs hHTg-HF plus A-4166: 31.0 +/- 3.5 p < 0.03) and Rg' (Soleus muscle: hHTg-HF: 29.2 +/- 3.2 vs hHTg-HF plus A-4166: 41.3 +/- 4.0) to values of the control group on BD. In summary, a) a single bolus administration of A-4166 to the control or to the insulin resistant hHTg rats, fed either the BD or HF diets, did not abolish the reduction of GIR required to maintain euglycemia during hyperinsulinemic clamps; b) nevertheless, A-4166 caused a significant increase of the estimated plasma glucose disposal (Rd) and skeletal muscle glucose metabolic index (Rg') of hHTG rats fed the HF diet; c) we suggest that A-4166 may have an extrapancreatic action but this needs to be proven using a long-term administration plan of A-4166.Keywords
This publication has 10 references indexed in Scilit:
- Mechanisms of Liver and Muscle Insulin Resistance Induced by Chronic High-Fat FeedingDiabetes, 1997
- New non-sulfonylurea insulin secretagoguesExpert Opinion on Investigational Drugs, 1997
- Hereditary Hypertriglyceridemic Rat: A New Animal Model of Metabolic Alterations in HypertensionBlood Pressure, 1995
- A novel D-phenylalanine-derivative hypoglycemic agent A-4166 increases cytosolic free Ca2+ in rat pancreatic beta-cells by stimulating Ca2+ influx.Endocrinology, 1994
- High Fat Diet‐Induced Insulin ResistanceAnnals of the New York Academy of Sciences, 1993
- In vivo insulin responsiveness for glucose uptake and production at eu- and hyperglycemic levels in normal and diabetic ratsBiochimica et Biophysica Acta (BBA) - General Subjects, 1992
- Possibility of ideal blood glucose control by a new oral hypoglycemic agent, N-[(trans-4-isopropylcyclohexyl)-carbonyl]-d-phenylalanine (A-4166), and its stimulatory effect on insulin secretion in animalsDiabetes Research and Clinical Practice, 1991
- A potent in vivo effect of ciglitazone on muscle insulin resistance induced by high fat feeding of ratsMetabolism, 1989
- Normal Insulin Sensitivity of the Islets of Langerhans in Obese Subjects with Resistance to Its Glucoregulatory ActionsDiabetes, 1984
- Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agentDiabetes, 1983